Drug intelligence / Profile preview

CRIS115

Development stage: Phase 1
Lead developer: Cristália
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CRIS115 is an intravenous liposomal dispersion developed by Cristália Produtos Químicos Farmacêuticos Ltda. for the treatment of drug overdose. It is designed as a "rescue liposome" therapy, utilizing a mechanism often referred to as a "lipid sink." By introducing lipid vesicles into the bloodstream, the drug aims to sequester lipophilic toxins and medications—such as local anesthetics, tricyclic antidepressants, or calcium channel blockers—away from target organs like the heart and brain, thereby mitigating systemic toxicity. It is currently being evaluated in Phase 1 clinical trials for safety, tolerability, and pharmacokinetics in healthy participants.

Other names: Rescue Liposomeliposome rescueliposomal dispersion

Beyond the preview

Go deeper on CRIS115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRIS115.

Explore the full profile